UCB SA (OTCMKTS:UCBJY) Short Interest Down 95.9% in October

UCB SA (OTCMKTS:UCBJY) saw a large decline in short interest in the month of October. As of October 31st, there was short interest totalling 3,000 shares, a decline of 95.9% from the October 15th total of 73,100 shares. Based on an average daily trading volume, of 47,400 shares, the short-interest ratio is presently 0.1 days.

UCB Stock Down 0.3 %

UCBJY stock opened at $96.31 on Thursday. The company has a debt-to-equity ratio of 0.33, a quick ratio of 0.78 and a current ratio of 1.19. The business has a fifty day simple moving average of $93.21 and a 200-day simple moving average of $82.27. UCB has a 52 week low of $36.18 and a 52 week high of $99.40.

UCB Company Profile

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.